~~<i id='3BB77798DE'><strike id='3BB77798DE'><tt id='3BB77798DE'><pre id='3BB77798DE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：entertainment 2025-10-01 21:41:07 - browse：3748

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Test for long Covid? Researchers find new clue in blood samples

leisure time

hotspot

knowledge

focus

explore

hotspot

AdobeWhenpatientsgoshoppingtoday,theymightfindthemselvescheckingoutwithmorethanthevitaminsorbulktoil

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

Research misconduct: Proposed new rules face resistance

AI generated plenty of interest at JPM but not a lot of trust

Elizabeth Holmes banned from government health programs

My yearlong odyssey to get my son’s ADHD medication covered

Francis Collins on trust in science and how Covid communications failed

focus

entertainment

leisure time

Cancer drug shortages should be causing more outrage

Independent physicians launch a new lobbying group

Hepatitis C has a cure — but many Americans still lack access to it

Traditional Chinese medicine benefits explored in new JAMA study

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Apple is now the first public company to be valued at $3 trillion

Eli Lilly, Pfizer, and others want in on the online prescription market

Dobbs anniversary: the lost opportunity of abortion as health care

Francis Collins on trust in science and how Covid communications failed

hotspot

Biotech venture capitalists face new demands from investors

The pink breast cancer awareness ribbon needs a redesign

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The pink breast cancer awareness ribbon needs a redesign

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

FDA has safety concerns on CRISPR

knowledge

focus

explore

hotspot